Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Rating of “Hold” from Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has been assigned a consensus rating of “Hold” from the nine research firms that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $11.31.

A number of equities research analysts have recently commented on DH shares. Barclays increased their price objective on Definitive Healthcare from $10.00 to $11.00 and gave the company an “equal weight” rating in a research report on Friday, March 1st. Stifel Nicolaus decreased their price target on Definitive Healthcare from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, January 17th. Canaccord Genuity Group lifted their price target on Definitive Healthcare from $9.00 to $10.00 and gave the stock a “hold” rating in a research note on Thursday, February 29th. Canaccord Genuity Group lowered shares of Definitive Healthcare from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Finally, Needham & Company LLC downgraded shares of Definitive Healthcare from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th.

Definitive Healthcare Price Performance

Shares of Definitive Healthcare stock opened at $7.15 on Tuesday. Definitive Healthcare has a 52 week low of $5.53 and a 52 week high of $12.45. The company has a current ratio of 2.31, a quick ratio of 2.31 and a debt-to-equity ratio of 0.20. The company’s 50-day moving average price is $8.04 and its two-hundred day moving average price is $8.31. The stock has a market cap of $842.20 million, a PE ratio of -4.02, a price-to-earnings-growth ratio of 6.09 and a beta of 1.39.

Definitive Healthcare (NASDAQ:DH) last released its earnings results on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.02). The business had revenue of $65.93 million during the quarter, compared to the consensus estimate of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. As a group, sell-side analysts anticipate that Definitive Healthcare will post 0.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Large investors have recently made changes to their positions in the business. Massachusetts Financial Services Co. MA grew its holdings in shares of Definitive Healthcare by 76.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,466,514 shares of the company’s stock valued at $34,457,000 after acquiring an additional 1,496,652 shares in the last quarter. Conestoga Capital Advisors LLC grew its stake in Definitive Healthcare by 12.1% in the fourth quarter. Conestoga Capital Advisors LLC now owns 5,521,137 shares of the company’s stock valued at $54,880,000 after purchasing an additional 595,280 shares in the last quarter. Vanguard Group Inc. increased its position in Definitive Healthcare by 6.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,331,543 shares of the company’s stock worth $34,609,000 after purchasing an additional 254,726 shares during the last quarter. Raymond James & Associates raised its stake in shares of Definitive Healthcare by 41.6% during the 1st quarter. Raymond James & Associates now owns 844,814 shares of the company’s stock worth $6,818,000 after purchasing an additional 248,266 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Definitive Healthcare by 11.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,090,136 shares of the company’s stock valued at $8,710,000 after buying an additional 113,963 shares during the last quarter. Institutional investors and hedge funds own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.